Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the 'future' in dermatology therapeutics? (Q38489705)

3 September 2017

1 reference

title

Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the 'future' in dermatology therapeutics? (English)

1 reference

3 September 2017

Mrinal Gupta

1

1 reference

3 September 2017

Vikram K Mahajan

2

1 reference

3 September 2017

Karaninder S Mehta

3

1 reference

3 September 2017

Pushpinder S Chauhan

4

1 reference

3 September 2017

Ritu Rawat

5

1 reference

3 September 2017

19 May 2015

1 reference

Archives of Dermatological Research

3 September 2017

1 reference

3 September 2017

307

1 reference

3 September 2017

9

1 reference

3 September 2017

767-780

1 reference

https://scigraph.springernature.com/pub.10.1007/s00403-015-1571-1

3 September 2017

0 references

cites work

New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

In vitro and in vivo anti-melanoma effects of ciglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Expression of peroxisome proliferator-activated receptor and CCAAT/enhancer binding protein transcription factors in cultured human sebocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Antiangiogenic therapy with pioglitazone, rofecoxib, and trofosfamide in a patient with endemic kaposi sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

PPARgamma expression profile and its cytokine driven regulation in atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Functions of peroxisome proliferator-activated receptors (PPAR) in skin homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Epithelium-mesenchyme interactions control the activity of peroxisome proliferator-activated receptor beta/delta during hair follicle development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

The benefits of sunflower oleodistillate (SOD) in pediatric dermatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Anti-proliferative effect of peroxisome proliferator-activated receptor gamma agonists on human malignant melanoma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Peroxisome proliferator-activated receptors and their relevance to dermatology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Peroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Inhibition of melanoma metastases by fenofibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Skin-targeted inhibition of PPAR β/δ by selective antagonists to treat PPAR β/δ-mediated psoriasis-like skin disease in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Fetal epidermal differentiation and barrier development In vivo is accelerated by nuclear hormone receptor activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

The nuclear receptor PPAR gamma is expressed by mouse T lymphocytes and PPAR gamma agonists induce apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Functions of the peroxisome proliferator-activated receptor (PPAR) alpha and beta in skin homeostasis, epithelial repair, and morphogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Peroxisome proliferator-activated receptor delta agonists inhibit T helper type 1 (Th1) and Th17 responses in experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Expression and function of peroxisome proliferator-activated receptors in human melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Ligands and activators of nuclear hormone receptors regulate epidermal differentiation during fetal rat skin development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Keratinocyte differentiation in hyperproliferative epidermis: topical application of PPARalpha activators restores tissue homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Peroxisome proliferator-activated receptors in cutaneous biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Effect of topical PPARbeta/delta and PPARgamma agonists on plaque psoriasis. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

The efficacy of methotrexate plus pioglitazone vs. methotrexate alone in the management of patients with plaque-type psoriasis: a single-blinded randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Growth inhibition and differentiation induced by peroxisome proliferator activated receptor gamma ligand rosiglitazone in human melanoma cell line A375.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Long-term treatment experience in a subject with Dunnigan-type familial partial lipodystrophy: efficacy of rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Deficiency of PPARbeta/delta in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Peroxisome-proliferator-activated receptor (PPAR)-gamma activation stimulates keratinocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Critical role of peroxisome proliferator-activated receptor gamma on anoikis and invasion of squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)alpha and PPARbeta mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

PPARbeta activation inhibits melanoma cell proliferation involving repression of the Wilms' tumour suppressor WT1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Lichen planopilaris treated with a peroxisome proliferator-activated receptor gamma agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Contributions of peroxisome proliferator-activated receptor β/δ to skin health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Agonists of peroxisome proliferator-activated receptor gamma inhibit cell growth in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

PPARgamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Therapeutic potential of thiazolidinediones as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

The effect of PPAR?? ligands on the proliferation and apoptosis of human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Early cutaneous gene transcription changes in adult atopic dermatitis and potential clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

PPARs and molecular mechanisms of transrepression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Activation of PPARbeta/delta causes a psoriasis-like skin disease in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Inhibition of IgE-production by peroxisome proliferator-activated receptor ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Role of PPAR, LXR, and PXR in epidermal homeostasis and inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Role of peroxisome proliferator-activated receptor alpha in epidermal development in utero

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Peroxisome proliferator-activated receptor activators protect sebocytes from apoptosis: a new treatment modality for acne?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Peroxisome proliferator-activated receptors (PPARs) in dermatology: Challenge and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Peroxisome proliferator-activated receptors (PPARs) and the human skin: importance of PPARs in skin physiology and dermatologic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferator activated receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Peroxisomes in dermatology. Part II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Critical roles of PPAR beta/delta in keratinocyte response to inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Activators of peroxisome proliferator-activated receptor-alpha partially inhibit mouse skin tumor promotion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Efficacy of dioic acid compared with hydroquinone in the treatment of melasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Peroxisome proliferator-activated receptors increase human sebum production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

A new mechanism of action for skin whitening agents: binding to the peroxisome proliferator-activated receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Differentiation and apoptosis in human immortalized sebocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

Zileuton, a new efficient and safe systemic anti-acne drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00403-015-1571-1

10.1007/S00403-015-1571-1

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

0 references

1 reference